Arrhythmias & electrophysiology
A randomized comparison of comprehensive weight loss intervention vs. usual care on recurrences of atrial fibrillation in obese patients after catheter ablation: HOBIT-AF trial
Authors' conclusion
HOBIT-AF trial showed that despite the beneficial effect of body weight reduction on metabolic profile of obese patients with predominantly paroxysmal AF after CA, no reduction in AF/AT recurrence was observed in comparison with control patients. This may be likely due to low AF burden after previous CA, limiting further improvement.
Study context
- Population
- Obese individuals after catheter ablation (CA) for atrial fibrillation (AF)aged 59 years, body mass index of 35.6 kg/m², randomized
- Participants
- 167 individuals
- Comparison
- Complex weight loss interventions vs control group
- Active groupn = 85
- Control groupn = 82
- Primary endpoint
- Change in AF/atrial tachycardia (AT) burden assessed from baseline and the final 14-day Holter monitoring
Primary result
As reported in the abstract
Active group
0.6 ± 2.5%
change · 95% CI −4.2–5.5%
Control group
−0.9 ± 1.8%
change · 95% CI −4.5–3.0%
Further findings
AF/AT recurrence-free survival · 3-18-month follow-up period · comparable between groups
Body weight · At the end of the treatment period
- Mean reduction of the initial body weight in the active group, accompanied by improvement of metabolic parameters
- 6.8 ± 7.0%
Original publication
A randomized comparison of comprehensive weight loss intervention vs. usual care on recurrences of atrial fibrillation in obese patients after catheter ablation: HOBIT-AF trial. Europace. Published 4 November 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →